PharmTeam

Seth Robey

Seth has always had a passion for scientific discovery, particularly biology and medicine. Seth studied biochemistry at Brandeis University. Now, as a PhD student of Molecular Pharmacology at Columbia University, Seth studies the drugs that help treat cardiac arrhythmias. He's thrilled to be a Motley Fool Contributor, and uncover new and exciting scientific discoveries that could improve our approach to medicine, and provide strong long term investments. Follow @SethRobey on twitter.

PharmTeam’s Activity

Fri Oct 24

NL

Article

PharmTeam published an article 12:40 PM

3 Reasons Thermo Fisher Scientific Inc.'s Stock Could Tumble

Can Thermo Fisher Scientific execute on its massive growth opportunity, or will the doldrums of slow organic growth hold back its stock?

Thu Oct 23

NL

Article

PharmTeam published an article 11:59 AM

Eli Lilly & Co. Earnings: Patent Pains Continue

Eli Lilly has experienced one of the toughest patent loss challenges in the industry. Did they finally reach the bottom this quarter?

Wed Oct 22

NL

Article

PharmTeam published an article 6:15 PM

Thermo Fisher Scientific Inc.'s Earnings: Buying Its Way to the Top

The laboratory equipment juggernaut showed explosive growth, but the market wasn't so impressed. Does Wall Street have this one backwards?

NL

Article

PharmTeam published an article 12:49 PM

3 Reasons Thermo Fisher Scientific Inc.'s Stock Could Rise

Thermo Fisher Scientific's future rests on three pillars of growth, and a big-name acquisition may tip the scales in their favor.

Tue Oct 21

NL

Article

PharmTeam published an article 9:40 AM

Is It Time to Buy Eli Lilly & Co.'s Stock?

Eli Lilly & Co. is promising big things, but has optimism in the stock gotten ahead of reality? It's time to ask if now's the right time to invest.

Mon Oct 20

NL

Article

PharmTeam published an article 3:00 PM

5 Things Thermo Fisher Scientific Inc.'s Management Wants You to Know

Thermo Fisher Scientific is in a strong position to exploit a growing genomics market. Management knows it -- and they really want you to know it, too.

Mon Oct 13

PharmTeam recommended TMFInnovator's post on a Motley Fool Rule Breakers board. 11:24 PM

Fri Oct 3

CAPS Outperform Pitch

PharmTeam wrote about ESPERION THERAPEUTICS INC (ESPR) . 9:41 AM

ESPR Outperform

The data and market opportunity from ECT-1002 look fantastic. The company is fairly well capitalized and has no debt. Unlike other development stage biotechs, further dilution doesn't seem to be a huge risk because the company is fairly well [more]

Caps Pick

PharmTeam made a pick in CAPS. 9:41 AM

ESPERION THERAPEUTICS INC (ESPR) will Outperform the S&P 500

Fri Sep 26

Caps Pick

PharmTeam made a pick in CAPS. 4:00 PM

Regeneron Pharmaceuticals, Inc. (REGN) will Outperform the S&P 500

Caps Pick

PharmTeam made a pick in CAPS. 3:58 PM

InvenSense (INVN) will Outperform the S&P 500

Wed Sep 24

Rule Breakers Boards Post

PharmTeam replied to the Rule Breakers boards. 9:32 PM

Mon Sep 22

NL

Article

PharmTeam published an article 11:54 PM

3 Reasons Eli Lilly & Co.'s Stock Could Fall

Management at Eli Lilly & Co. has faced a mountain of challenges in the wake of debilitating patent losses, but the stock has held strong regardless. Here are three reasons that rally may not continue into the future.

Fri Sep 19

Rule Breakers Boards Post

PharmTeam posted to the Rule Breakers boards. 11:12 AM

Thu Sep 4

Rule Breakers Boards Post

PharmTeam replied to the Rule Breakers boards. 9:06 PM

Rule Breakers Boards Post

PharmTeam replied to the Rule Breakers boards. 8:12 PM

Tue Sep 2

Stock Advisor Boards Post

PharmTeam replied to the Stock Advisor boards. 10:27 AM

Fri Aug 29

NL

Article

PharmTeam published an article 11:36 AM

3 Reasons Eli Lilly & Co.'s Stock Could Rise

With earnings tumbling over the patent cliff, can diabetes and oncology transform Eli Lilly into a Big Pharma turnaround story?

Thu Aug 21

Stock Advisor Boards Post

PharmTeam posted to the Stock Advisor boards. 9:33 AM

Wed Aug 20

NL

Article

PharmTeam published an article 5:59 PM

5 Things Eli Lilly and Co's Management Wants You to Know

At a critical time for the company, Eli Lilly's management has laid out its plans to return to growth and gave us a good look at what the future holds.

Show More Activity ...

CAPS Stats & Trivia

CAPS Player Rating 87.58
Player Rank 9326 out of 75058
Score 628.56
Score Change Today +21.28
Accuracy 59.21%
Active Picks 55
Total Picks 76
Best Pick ILMN (+151.13)
Worst Pick CYTK (-76.67)
Average Score per Pick 8.27
Charms Earned 5
Highest Rated Favorite No Favorites Selected
Go to PharmTeam’s CAPS page

Boards Stats & Trivia

CAPS All Star
Board Posts 31
Recs Received 34
People who have rec'd these posts 23
Recs to Posts Ratio (last 30 days) N/A
Threads Started 11
Threads Started Percentage 35.48 %
Most Frequent Board Motley Fool Rule Breakers
Very First Post A SAS: Amazon.com post. (12/1/2013)
Percentage of Posts Rec'd 51.61 %
Show PharmTeam’s 10 Latest Posts